HAFSLUND GOES FOR ITALIAN MARKET
The Norwegian pharmaceutical and diagnostics company Hafslund Nycomed has started operations in Italy through its Milan-based subsidiary, and is about to register with the Italian authorities two new products.
The move is viewed by Italian sources as a direct attack on Bracco's dominant position on the Italian market for diagnostic imaging agents which is valued at some 120 billion lire ($97.8 million) annually. Bracco, an Italian company, controls 62% of the domestic market, comprising X-ray contrast media, ultrasound and magnetic resonance imaging compounds.
The remaining 30% of the market is actually held by Hafslund's Omnipaque, which has been sold under license in Italy by Schering AG. The latter, meantime, is the licensee for Bracco's Iopamiro on the French and Japanese markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze